LinkedIn Profile

Access Cleveland BioLabs historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:cbli 824669 Apr 14th, 2024 12:00AM Cleveland Biolabs 717 21.00 Open Apr 13th, 2024 10:45PM Apr 13th, 2024 10:45PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 13th, 2024 12:00AM Cleveland Biolabs 717 21.00 Open Apr 12th, 2024 10:36PM Apr 13th, 2024 11:11AM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 12th, 2024 12:00AM Cleveland Biolabs 717 21.00 Open Apr 11th, 2024 10:40PM Apr 12th, 2024 08:06AM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 11th, 2024 12:00AM Cleveland Biolabs 717 21.00 Open Apr 10th, 2024 11:10PM Apr 11th, 2024 10:50AM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 10th, 2024 12:00AM Cleveland Biolabs 717 21.00 Open Apr 9th, 2024 10:43PM Apr 10th, 2024 04:59PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 9th, 2024 12:00AM Cleveland Biolabs 716 21.00 Open Apr 8th, 2024 10:54PM Apr 9th, 2024 09:40AM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 8th, 2024 12:00AM Cleveland Biolabs 716 21.00 Open Apr 7th, 2024 11:20PM Apr 8th, 2024 06:38PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 7th, 2024 12:00AM Cleveland Biolabs 716 21.00 Open Apr 6th, 2024 10:51PM Apr 6th, 2024 10:51PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 6th, 2024 12:00AM Cleveland Biolabs 715 21.00 Open Apr 5th, 2024 10:51PM Apr 5th, 2024 10:51PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology
nasdaq:cbli 824669 Apr 5th, 2024 12:00AM Cleveland Biolabs 716 21.00 Open Apr 4th, 2024 11:14PM Apr 4th, 2024 11:14PM Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc. Open oncology, radiation countermeasure, and orphan drugs Open 73 High St Buffalo NY US 14203 Cleveland BioLabs Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.